

Plant cell factories and mucosal vaccines

Amanda M Walmsley* and Charles J Arntzen†

Many advances continue to be made in the field of plant-derived vaccines. Plants have been shown capable of expressing a multicomponent vaccine that when orally delivered induces a T-helper cell subset 1 response and enables passive immunization. Furthermore, a plant-derived vaccine has been shown to protect against challenge in the target host. Increased antigen expression levels (up to 4.1% total soluble protein) have been obtained through transformation of the chloroplast genome. In view of these findings, plant-derived vaccines have been proved as valuable commodities to the world's health system; however, before their application, studies need to focus on optimization of immunization strategies and to investigate antigen stability.

Addresses

Department of Plant Biology, Arizona State University,
Tempe AZ 85287, USA

*e-mail: amanda.walmsley@asu.edu

†e-mail: charles.arntzen@asu.edu

Current Opinion in Biotechnology 2003, **14**:145–150

This review comes from a themed section on
Plant biotechnology
Edited by Csaba Koncz

0958-1669/03/\$ – see front matter
© 2003 Elsevier Science Ltd. All rights reserved.

DOI 10.1016/S0958-1669(03)00026-0

Abbreviations

CTB	cholera toxin B subunit
ETEC	enterotoxigenic <i>Escherichia coli</i>
FDA	Food and Drug Administration
FMDV	foot and mouth disease virus
HBsAg	hepatitis B surface antigen
LTB	heat-labile toxin of ETEC B subunit
MV	measles virus
TGEV	transmissible gastroenteritis coronavirus
TMV	tobacco mosaic virus
TSP	total soluble protein

Introduction

Emerging and re-emerging diseases, the increasing age and size of the world's population and the threat of biological warfare are challenging the research, development and production arenas of the pharmaceutical industry. There are many effective avenues for the production of recombinant pharmaceutical proteins; however, the main challenge lies in achieving cost-effective production on a large scale. Over the past five years the potential for using plants as bioreactors has become well established. Plant systems offer several advantages: they are economical, using low-cost inputs such as light, water and miner-

als; they are easily adaptable to large-scale operations (by growing more plants); they possess minimal risk of contamination with potential human pathogens; the products may not require purification and pharmaceuticals produced this way can be given mucosally, hence simplifying delivery and decreasing overall cost.

Plant-derived pharmaceuticals can be categorized into three areas: antibodies, biopharmaceuticals, and vaccines. Plant-derived antibodies, also referred to as plantibodies, have extensive uses in many areas including bioremediation, disease resistance in plants and industrial purification processes. The most advanced application of plantibodies, however, is the production of antibodies for medical use. Stoger and colleagues [1] provided a recent review on plant-derived antibodies.

There have been many reports of biopharmaceutical expression in plants and these proteins have a diverse range of applications [2–9] (see Table 1). In general, however, expression levels of these plant-derived biopharmaceuticals need to be increased before commercial production can be accomplished [10].

In the past 12 years, substantial research has shown that plant-derived vaccines are feasible commodities. Walmsley and Arntzen give a general description of this technology and its early development [11]. This review highlights the advances made in the past three years and the future directions for the development of plant-derived vaccines.

Developing antigen expression

Subunit vaccines comprise specific macromolecules that induce a protective immune response against a pathogen. The use of plants to express antigens for use as vaccines has seen continued interest over the past few years, as witnessed by an increasing number of reports of transgenic plant expression of new antigens and the altered expression of previously reported antigens. A range of different plant and vector systems for the expression of antigens have been investigated and some are summarized in Table 2 [12–20]. Seed-specific production of the B subunit of heat-labile toxin (LTB) by Streatfield *et al.* [19] achieved LTB expression levels reaching 1.8% total soluble protein (TSP) and two separate maize breeding programs have increased antigen production by fivefold [19] and tenfold [20]. The investigations of Chikwamba *et al.* [20] regarding expression of LTB in maize are also the first to report the use of particle bombardment for the production of plant-derived vaccines. Immunogenicity was demonstrated for hepatitis B surface antigen (HBsAg)

Table 1**Applications of biopharmaceuticals produced in plants.**

Application	Reference
Anticoagulants	[2]
Thrombin inhibitors	[2]
Growth hormones	[3]
Blood substitutes	[2,4]
Collagen replacement	[5]
Antimicrobial agents	[6]
Treatment and/or prevention of neutropenia	[7]
Treatment and/or prevention of anaemia	[8]
Treatment and/or prevention of hepatitis	[2]
Treatment and/or prevention of cystic fibrosis, liver diseases and haemorrhage	[7]
Treatment and/or prevention of Gaucher's disease	[2]
Treatment and/or prevention of HIV	[7]
Treatment and/or prevention of hypertension	[7]
Treatment and/or prevention of organophosphate poisoning	[9]

[12,21], the S protein of transmissible gastroenteritis coronavirus (TGEV) [13,14] and a human immunodeficiency virus 1 (HIV-1) epitope [16], while successful challenge trials resulted after immunization with *P. aeruginosa* epitopes [15], the FP1 epitope of foot and mouth disease virus (FMDV) [17] and LTB [20].

Additional antigens expressed in plants include the respiratory syncytial virus (RSV) G and F proteins [22,23], the VP6 protein of rotavirus [24–26], the measles virus (MV) hemagglutinin (H) protein [27], and an epitope from the major surface antigen of *Plasmodium falciparum* (PfMSP1) [28]. Although the immunogenicity of the plant-derived RSV G and F proteins and the measles virus H protein were demonstrated in animal trials, the immunogenicity of the VP6 antigen and the PfMSP1 epitope were not tested.

The development of plant-derived vaccine technology

Vaccines in clinical trials

The second report of clinical trials carried out with a plant-derived vaccine appeared in 2000 [29]. Transgenic potatoes expressing the Norwalk virus capsid protein

(NVCP) under control of the tuber-specific patatin promoter were orally delivered to human volunteers in phase I/II clinical trials. Of the total number of volunteers who ingested the transgenic potatoes, 95% developed significant increases in specific IgA antibody-secreting cells while 20% developed specific serum IgG and 30% developed specific stool IgA. Although the increase in specific serum antibodies was modest, the use of adjuvants, improved assembly of NV-like particles and increased dosage of the recombinant protein may improve the NVCP immunogenicity (see Update).

Plastid transformation

Transformation of the plastid genome offers several advantages for antigen expression, including high-level foreign protein expression, removal of the threat of gene silencing, and transgene containment owing to lack of pollen transmission. Daniell *et al.* [30] published the first report of a plant-derived vaccine developed through chloroplast transformation. Integration of an unmodified cholera toxin B subunit (CTB)-coding region into the chloroplast genome resulted in the accumulation of up to 4.1% TSP in tobacco leaves. GM₁ ganglioside-dependent binding assays showed the chloroplast-synthesized CTB to retain its ability to bind to the intestinal membrane receptor; however, immunogenicity studies were not performed.

Targeting antigens

In attempts to facilitate the harvesting of proteins, antigens have been expressed in a tissue-specific manner in maize kernels [19], tomato fruit [23] and seeds of transgenic tobacco [31]. Targeting of the major glycoprotein (gB) of human cytomegalovirus (HCMV) to transgenic tobacco seeds was previously described [32], and further investigations showed that recombinant gB was almost exclusively deposited in protein storage vesicles in mature tobacco seeds [31].

Fusion proteins

Owing to their minimalistic nature, subunit vaccines are often difficult to detect in a recombinant protein expression system and/or ineffective at inducing the mucosal immune system. Additional proteins are therefore often

Table 2**Plant and vector systems developed for antigen expression.**

Plant or vector expression system	Antigen	Reference
Potato	Hepatitis B surface antigen (HBsAg)	[12]
Potato and tobacco	N-terminal domain of the spike protein (S) from transmissible gastroenteritis coronavirus	[13,14]
Tobacco mosaic virus and influenza vector	<i>Pseudomonas aeruginosa</i> F protein	
Potato virus X (PVX) vector	Human immunodeficiency virus type 1	[16]
Potato	VP1 epitope of foot and mouth disease virus	[17]
Tomato	B subunits of the cholera toxin of <i>Vibrio cholerae</i> (CTB)	[18]
Maize	B subunits of the heat labile toxin (LTB) of enterotoxigenic <i>Escherichia coli</i>	[19,20]

employed to either improve the detection or immunogenicity of a subunit vaccine. Both Gil *et al.* [33] and Dus Santos *et al.* [34] fused antigens to the gene encoding β -glucuronidase (GUS) to increase ease of detection within the plant expression system. In both instances, transformants were selected on the basis of GUS activity. The GUS fusion to both the 2L21 protective epitope from canine parvovirus [33] and protective epitope from FMDV [34] proved immunogenic. Additionally, mice immunized with the GUS–FMDV epitope fusion were completely protected against challenge with the native virus.

Cholera toxin (CT) has been used effectively as a targeting protein within plant-derived vaccines. Nemchinov *et al.* [35] described tobacco mosaic virus (TMV) expression of a *Vibrio cholerae* CTB fusion to an epitope (HVR1) from the hepatitis C virus (HCV). Tobacco plants inoculated with the recombinant TMV produced the HVR1 epitope fused to a functionally active, pentameric CTB. The plant-derived CTB–HVR1 reacted with HVR1-specific monoclonal antibodies and sera from individuals infected with virus from four of the major genotypes of HCV. Intranasal immunization of mice with a crude plant extract containing the recombinant CTB–HVR1 elicited both anti-CTB serum antibody and anti-HVR1 serum antibody that specifically bound to HCV-like particles.

An epitope of the rotavirus enterotoxin protein (NSP4) has also been fused to CTB and expressed in potatoes [36]. Expressing a multicomponent CT fusion vaccine in potato expanded this work. The vaccine consisted of the CTB–NSP4 epitope fusion and an ETEC fimbrial antigen fusion to the component of CTA that associates the A subunit to the CTB subunit (CTA2) [37**]. The two fusion proteins assembled into cholera holotoxin-like structures that retained enterocyte-binding affinity. Orally immunized mice generated detectable levels of serum and mucosal antibodies specific for the native antigen. Elevated levels of interleukin-2 (IL-2) and interferon- γ (IFN- γ) were detected in immunogen-challenged spleen cells from the immunized mice. This indicated the presence of a strong T-helper cell subset 1 (TH1) immune response to the three plant-synthesized antigens. This result was supported by the demonstration of a significant increase in CD4+ lymphocyte numbers. Diarrheal symptoms were reduced in severity and duration in passively immunized mouse neonates following rotavirus challenge. This paper represents the first report of a multicomponent, plant-derived vaccine. This work also demonstrates for the first time passive immunization through a plant-derived vaccine and the induction of a TH1 immune response by an orally delivered, plant-derived vaccine.

Optimizing delivery

The vaccination strategy and schedule can have a significant effect on the immune response developed.

Lauterslager *et al.* [38] investigated the efficacy of a potato-derived LTB vaccine in mice. It was determined that oral administration of plant-derived LTB elicits a systemic and local IgA response in parentally primed, but not naïve, animals. This was in contrast to the results reported by Haq *et al.* [39] and Mason *et al.* [40] who reported significant specific antibody responses in naïve animals and showed protection from challenge [40]. The authors' explanations included an inadequate immunization schedule, low antigen dose, low antigen immunogenicity, inability to accurately detect antibodies and interference of tuber material in assays. As tuber materials did not interfere in previous studies performed with the same potato variety [39,40], and unsuccessful challenge trials indicated either low or non-existent antibody titers, this investigation highlights the importance of immunization regime and antigen dosage.

After establishing the immunogenicity of plant-derived MV H protein in mice trials [27], Webster *et al.* [41*] optimized the dose of plant material required to obtain high titer, MV-specific, neutralizing antibodies and examined the boosting of MV H DNA immunization with the plant-derived vaccine. A single-dose DNA inoculation followed by multiple, orally delivered, plant-derived boosters, induced significantly greater quantities of MV-neutralizing antibodies than immunization with DNA or plant-derived vaccine alone. This paper reports the first demonstration of an enhanced immune response to a prime-boost vaccination strategy combining a DNA vaccine with orally delivered plant-derived vaccines.

Stability and processing of plant-derived vaccines

Reliable methods are needed to quantify plant-derived antigens and ensure their stability. Lee *et al.* [42] performed preliminary stability studies. Clover plants expressing the *Mannheimia haemolytica* A1 leukotoxin 50 fusion protein were harvested and allowed to dry at room temperature and ambient humidity for one to four days. After three days, the clover tissue retained approximately 20% of its initial fresh weight; however, no significant degradation of the fusion protein was observed. Hence, the fusion protein did not require refrigeration for stability. The clover-expressed fusion protein induced an immune response in injected rabbits that recognized and neutralized the native antigen in modified neutral red cytotoxicity assays.

Smith *et al.* [43*] performed a more comprehensive stability study. The quantification of antigenically reactive HBsAg was found to be strongly dependent on the ratio of detergent:cell concentration. A 1–20% w/v sodium ascorbate concentration in the extraction buffer improved the measured levels of monoclonal-reactive antigen 4- to 12-fold. Detergent also influenced antigen stability in cell lysates stored at 4°C. Under optimum conditions

stability was maintained for at least one month, whereas excess detergent rendered the antigen susceptible to proteolytic degradation. Proteolysis was counteracted by the addition of skimmed milk or its protein component; this stabilized the antigen for up to two months. Also, by altering the sodium ascorbate concentration or buffer pH, the proportion of HBsAg displaying the monoclonal-reactive epitopes increased between 8- and 20-fold. Although antigen stability will have to be investigated on a case-by-case basis, it is obvious that simple *in vitro* manipulations may prove valuable in increasing the immunogenicity and stability of plant-derived antigens.

Castañón *et al.* [44] investigated minimal processing of a potato-derived rabbit hemorrhagic disease virus (RHDV) vaccine consisting of the VP60 gene. Harvested potatoes were peeled, cut into pieces, lyophilized, powdered, stored and used in trials within three months of collection. Rabbits were primed subcutaneously and boosted intramuscularly with extracts made from the potato powder. The rabbits immunized with the transgenic potato elicited specific antibody responses and were protected against challenge with virulent RDHV.

Conclusions

Evidence for plant expression systems leading to the improved manufacture and delivery of vaccines is in hand. Studies have proven plants capable of expression of many different antigens, all of which have demonstrated immunogenicity when tested and some have been shown to provide protection in model and target animals. It has often been stated that there is a need for increased antigen expression levels in plants; however, targeted expression and plant breeding have alleviated this problem. Preliminary investigations into antigen stability, processing and optimal immunization strategies have been performed. However, there is a need for further in-depth studies of individual antigens before plant-derived vaccines can be used as a commodity. Recently, concerns have been raised regarding the regulation of plant-derived vaccines and the safety of the food chain from contamination with these pharmaceuticals. For this reason the initial concept of edible, food-delivered vaccines needs to be developed into inexpensive, plant-derived, mucosal vaccines that are regulated through prescription and not released like other transgenic plants used for modern agricultural products. Within the United States, two entities currently regulate plant-derived pharmaceuticals, the US Department of Agriculture (USDA) and the Food and Drug Administration (FDA). The USDA currently regulates the location and containment of transgenic plants expressing pharmaceuticals, whereas the FDA ensures quality assurance and quality control. The FDA guarantees that quality assurance and quality control standards are maintained during production and preparation of the materials to ensure safety and efficacy of the materials before human administration. The FDA

also determines the relative risk of progressing plant-derived pharmaceuticals to licensure through phased clinical trial monitoring. Recently, the FDA released the first draft regulations for the production of plant-derived pharmaceuticals [45••]. The regulatory environment in the US is evolving to encourage the safe yet rapid commercialization of plant-derived pharmaceuticals. The recent developments in plant-derived vaccine production reported here bring this technology ever closer to graduating from the research and development phase. The co-evolution of plant-derived vaccine technology and production regulations is ensuring these prototype vaccines are close to becoming useful commodities.

Update

An additional human clinical trial with a plant-derived vaccine was reported in August of 2002 [46]. Transgenic spinach expressing epitopes from the rabies virus glycoprotein (G protein) and nucleoprotein (N protein) fused to the coat protein (CP) of alfalfa mosaic virus (AIMV) was orally delivered to 14 human volunteers. Five of the volunteers had been previously immunized with the conventional rabies vaccine. Three of the five volunteers who had previously been immunized with the conventional vaccine and five of the nine initially naive individuals showed significant specific antibody responses to the rabies virus while none of the control volunteer samples showed significant elevation in rabies-specific antibodies. Seven days after completing the feeding regime, the nine initially naive volunteers were given a dose of the conventional rabies virus vaccine. Three of these individuals showed rabies virus neutralizing antibodies, but none of the five controls showed these antibodies. Although no neutralizing antibody was detected before immunization with the commercial vaccine, there was a clear indication of the potential of the plant-derived rabies vaccine to act as a supplementary oral booster for rabies vaccinations.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
 - of outstanding interest
1. Stoger E, Sack M, Fischer R, Christou P: **Plantibodies: applications, advantages and bottlenecks.** *Curr Opin Biotechnol* 2002, **13**:161-166.
 2. Cramer CL, Boothe JG, Oishi KK: **Transgenic plants for therapeutic proteins: linking upstream and downstream strategies.** *Curr Top Microbiol Immunol* 1999, **240**:95-118.
 3. Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N, Paradkar V, Schlittler M, Carroll JA, Spatola L *et al.*: **High-yield production of a human therapeutic protein in tobacco chloroplasts.** *Nat Biotechnol* 2000, **18**:333-338.
 4. Farran I, Sanchez-Serrano JJ, Medina JF, Prieto J, Mingo-Castel AM: **Targeted expression of human serum albumin to potato tubers.** *Transgenic Res* 2002, **11**:337-346.
 5. Ruggiero F, Exposito JY, Bournat P, Gruber V, Perret S, Comte J, OLAGNIER B, GARRONE R, THEISEN M: **Triple helix assembly and processing of human collagen produced in transgenic tobacco plants.** *FEBS Lett* 2000, **469**:132-136.

6. Chong DK, Langridge WH: **Expression of full-length bioactive antimicrobial human lactoferrin in potato plants.** *Transgenic Res* 2000, **9**:71-78.
7. Giddings G, Allison G, Brooks D, Carter A: **Transgenic plants as factories for biopharmaceuticals.** *Nat Biotechnol* 2000, **18**:1151-1155.
8. Kusnadi AR, Nikolov ZL, Howard JA: **Production of recombinant proteins in transgenic plants: practical considerations.** *Biotechnol Bioeng* 1997, **56**:473-484.
9. Mor TS, Sternfeld M, Soreq H, Arntzen CJ, Mason HS: **Expression of recombinant human acetylcholinesterase in transgenic tomato plants.** *Biotechnol Bioeng* 2001, **75**:259-266.
10. Daniell H, Streatfield SJ, Wycoff K: **Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants.** *Trends Plant Sci* 2001, **6**:219-226.
11. Walmsley AM, Arntzen CJ: **Plants for delivery of edible vaccines.** *Curr Opin Biotechnol* 2000, **11**:126-129.
12. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS: **Production of hepatitis B surface antigen in transgenic plants for oral immunization.** *Nat Biotechnol* 2000, **18**:1167-1171.
13. Gomez N, Wigdorovitz A, Castanon S, Gil F, Ordas R, Borca MV, Escribano JM: **Oral immunogenicity of the plant-derived spike protein from swine-transmissible gastroenteritis coronavirus.** *Arch Virol* 2000, **145**:1725-1732.
14. Tuboly T, Yu W, Bailey A, Degrandis S, Du S, Erickson L, Nagy E: **Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants.** *Vaccine* 2000, **18**:2023-2028.
15. Gilleland HE, Gilleland LB, Staccek J, Harty RN, Garcia-Sastre A, Palese P, Brennan FR, Hamilton WD, Bendahmane M, Beachy RN: **Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against *Pseudomonas aeruginosa* lung infection.** *FEMS Immunol Med Microbiol* 2000, **27**:291-297.
16. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, Benvenuto E, Capone I: **Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.** *J Virol* 2001, **75**:8434-8439.
17. Carrillo C, Wigdorovitz A, Trono K, Dus Santos MJ, Castanon S, Sadir AM, Ordas R, Escribano JM, Borca MV: **Induction of a virus-specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants.** *Viral Immunol* 2001, **14**:49-57.
18. Jani D, Meena LS, Mohammad Q, Haq R, Singh Y, Sharma AK, Tyagi AK: **Expression of cholera toxin B subunit in transgenic tomato plants.** *Transgenic Res* 2002, **11**:447-454.
19. Streatfield SJ, Mayor JM, Barker DK, Brooks C, Lamphear BJ, Woodard SL, Beifuss KK, Vicuna DV, Massey LA, Horn ME *et al.*: **Development of an edible subunit vaccine in corn against enterotoxigenic strains of *Escherichia coli*.** *In Vitro Cell Dev Biol Plant* 2002, **38**:11-17.
20. Chikwamba RK, Cunnick J, Hathaway D, McMurray J, Mason H, Wang K: **A functional antigen in a practical crop: LT-B-producing maize protects mice against *Escherichia coli* heat labile enterotoxin (LT) and cholera toxin (CT).** *Transgenic Res* 2002, **11**:479-493.
21. Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y: **Oral immunization with hepatitis B surface antigen expressed in transgenic plants.** *Proc Natl Acad Sci USA* 2001, **98**:11539-11544.
22. Belanger H, Fleish N, Cox S, Bartman G, Deka D, Trudel M, Koprowski H, Yusibov V: **Human respiratory syncytial virus vaccine antigen produced in plants.** *FASEB J* 2000, **14**:2323-2328.
23. Sandhu JS, Krasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE: **Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response.** *Transgenic Res* 2000, **9**:127-135.
24. Chung IS, Kim CH, Kim KI, Hong SH, Park JK, Kim JK, Kim WY: **Production of recombinant rotavirus VP6 from a suspension culture of transgenic tomato (*Lycopersicon esculentum* Mill.) cells.** *Biotechnol Letts* 2000, **22**:251-255.
25. O'Brien GJ, Bryant CJ, Voogd C, Greenberg HB, Gardner RC, Bellamy AR: **Rotavirus VP6 expressed by PVX vectors in *Nicotiana benthamiana* coats PVX rods and also assembles into virus-like particles.** *Virology* 2000, **270**:444-453.
26. Kim CH, Kim KI, Hong SH, Lee YH, Chung IS: **Improved production of recombinant rotavirus VP6 in sodium butyrate-supplemented suspension cultures of transgenic tomato (*Lycopersicon esculentum* Mill.) cells.** *Biotechnol Letts* 2001, **23**:1061-1066.
27. Huang Z, Dry I, Webster D, Strugnelli R, Wesselingh S: **Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice.** *Vaccine* 2001, **19**:2163-2171.
28. Ghosh S, Malhotra P, Lalitha PV, Guha-Mukherjee S, Chauhan VS: **Expression of *Plasmodium falciparum* C-terminal region of merozoite surface protein (PfMSP1₁₉), a potential malaria vaccine candidate, in tobacco.** *Plant Sci* 2002, **162**:335-343.
29. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ: **Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes.** *J Infect Dis* 2000, **182**:302-305.
30. Daniell H, Lee SB, Panchal T, Wiebe PO: **Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts.** *J Mol Biol* 2001, **311**:1001-1009.
- The native CTB gene was transformed into tobacco chloroplasts and resulted in CTB expression levels of up to 4.1% TSP. This is the first report of transgenic chloroplasts manufacturing a plant-derived vaccine.
31. Wright KE, Prior F, Sardana R, Altosaar I, Dudani AK, Ganz PR, Tackaberry ES: **Sorting of glycoprotein B from human cytomegalovirus to protein storage vesicles in seeds of transgenic tobacco.** *Transgenic Res* 2001, **10**:177-181.
32. Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I, Ganz PR: **Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco.** *Vaccine* 1999, **17**:3020-3029.
33. Gil F, Brun A, Wigdorovitz A, Catala R, Martinez-Torrecuadrada JL, Casal I, Salinas J, Borca MV, Escribano JM: **High-yield expression of a viral peptide vaccine in transgenic plants.** *FEBS Lett* 2001, **488**:13-17.
34. Dus Santos MJ, Wigdorovitz A, Trono K, Rios RD, Franzone PM, Gil F, Moreno J, Carrillo C, Escribano JM, Borca MV: **A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants.** *Vaccine* 2002, **20**:1141-1147.
35. Nemchinov LG, Liang TJ, Rifaat MM, Mazyad HM, Hadidi A, Keith JM: **Development of a plant-derived subunit vaccine candidate against hepatitis C virus.** *Arch Virol* 2000, **145**:2557-2573.
36. Arakawa T, Yu J, Langridge WH: **Synthesis of a cholera toxin B subunit-rotavirus NSP4 fusion protein in potato.** *Plant Cell Reports* 2001, **20**:343-348.
37. Yu J, Langridge WH: **A plant-based multicomponent vaccine protects mice from enteric diseases.** *Nat Biotechnol* 2001, **19**:548-552.
- This is the first report of plants expressing a multicomponent vaccine, a plant-derived vaccine inducing a TH1 response and passive immunization resulting from a plant-derived vaccine.
38. Lauterslager TG, Florack DE, van der Wal TJ, Molthoff JW, Langeveld JP, Bosch D, Boersma WJ, Hilgers LA: **Oral immunisation of naive and primed animals with transgenic potato tubers expressing LT-B.** *Vaccine* 2001, **19**:2749-2755.
39. Haq TA, Mason HS, Clements JD, Arntzen CJ: **Oral immunization with a recombinant bacterial antigen produced in transgenic plants.** *Science* 1995, **268**:714-716.
40. Mason HS, Haq TA, Clements JD, Arntzen CJ: **Edible vaccine protects mice against *Escherichia coli* heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene.** *Vaccine* 1998, **16**:1336-1343.

41. Webster DE, Cooney ML, Huang Z, Drew DR, Ramshaw IA, Dry IB, Strugnell RA, Martin JL, Wesselingh SL: **Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine.** *J Virol* 2002, **76**:7910-7912.

The immunization strategy for a plant-derived MV vaccine was optimized and resulted in a significant increase in MV-neutralizing antibodies. This paper reports the first demonstration of an enhanced immune response to a prime-boost vaccination strategy combining a DNA vaccine with orally delivered plant-derived vaccines.

42. Lee RW, Strommer J, Hodgins D, Shewen PE, Niu Y, Lo RY: **Towards development of an edible vaccine against bovine pneumonic pasteurellosis using transgenic white clover expressing a *Mannheimia haemolytica* A1 leukotoxin 50 fusion protein.** *Infect Immun* 2001, **69**:5786-5793.

43. Smith ML, Keegan ME, Mason HS, Shuler ML: **Factors important in the extraction, stability and *in vitro* assembly of the hepatitis B surface antigen derived from recombinant plant systems.** *Biotechnol Prog* 2002, **18**:538-550.

This paper describes an in depth investigation into the stability of HBsAg. Detergent concentration, sodium ascorbate concentration, the presence

of skimmed milk (or its protein) and buffer pH were found to be important factors in antigen stability.

44. Castañón S, Martín-Alonso JM, Marin MS, Boga JA, Alonso P, Parra F, Ordas R: **The effect of the promoter on expression of VP60 gene from rabbit hemorrhagic disease virus in potato plants.** *Plant Sci* 2002, **162**:87-95.

45. Food and Drug Administration: **Draft 'Guidance for industry: drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals.'** *Fed Regist* 2002, **67**:57828-57829.

This draft document represents the FDA's current thinking on the regulation of plant-derived vaccines within the USA. It provides recommendations on the use of bioengineered plants or plant materials to produce pharmaceuticals and outlines important scientific questions and information that should be addressed before application of the technology.

46. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H: **Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine.** *Vaccine* 2002, **20**:3155-3164.